on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Interests in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed a Form 8.3 disclosure with the Irish Takeover Panel regarding its interests in Avadel Pharmaceuticals plc. As of December 1, 2025, Vanguard holds 5,581,777 US$0.01 ordinary shares, amounting to a 5.73% stake in Avadel. Notably, no derivatives or options were exercised in conjunction with this interest, and no related agreements have been reported.
The filing also details recent transactions involving Avadel's securities. Vanguard purchased 2,982 shares at USD 21.42 each and sold 67 shares at the same price. The disclosure confirms no other inducement agreements or derivative-related understanding were in place.
This move falls under Rule 8.3 of the Irish Takeover Rules, emphasizing transparency by those holding significant positions in relevant securities.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news